Adam Feuerstein on Muck Rack

Adam Feuerstein

As seen in: The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

New York Attorney General Investigation Adds to Mylan's EpiPen Woes — The government backlash against Mylan's ( MYL) sales practices for the EpiPen, its popular epinephrine auto-injector for severe allergies, shows no sign of ending. In the latest development, the New York Attorney General's office announced that it is investigating Mylan's EpiPen 4 Schools program, which supplies the lifesaving auto-injector to kindergartens, elementary, middle and high schools.

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease — Retrophin ( RTRX) announced positive results from a mid-stage clinical trial Wednesday in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan at more than twice the rate of patients receiving a control drug. The company's next step will be to meet with the U.S.

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene — The first, targeted blood cancer drug from Agios Pharmaceuticals ( AGIO) will be submitted for approval in the U.S. by the end of the year, faster than investors expected.

Allergan CEO: No More Predatory Drug Pricing — Allergan ( AGN) CEO Brent Saunders says he understands, and even agrees with, the public outcry over predatory drug pricing decisions. He doesn't mention any of the companies accused of price gouging and profiteering recently, but he's clearly referring to Valeant Pharmaceuticals ( VRX) , Mylan ( MYL) and Turing.

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug — Karyopharm Therapeutics ( KPTI) announced results from a mid-stage clinical trial Tuesday in which an experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies. Based on Tuesday's results, Karyopharm intends to enroll additional advanced multiple myeloma patients into the study to collect more data.

Gilead Sinking Stock Price Calls Out for New Rescue Plan — There was a time when the underperformance of Gilead Sciences' ( GILD) stock price was viewed as an opportunity to buy shares of a historically great biotech company at a discount. But Gilead's stock price continues to fall, trading today where it did two years ago. The value play looks more like a trap.

Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug — Rigel Pharmaceuticals ( RIGL) said Tuesday that its experimental drug, fostamatinib, met the response rate primary endpoint in a phase III study of patients with an autoimmune platelet disease. The study showed that 18% of patients treated with fostamatinib achieved a stable platelet response compared to none receiving a placebo.

Mylan to Launch Cheaper Generic Alternative to EpiPen; Shares Rise — Mylan ( MYL) shares gained in Monday trading after announcing plans to launch a generic version of its EpiPen treatment for life-threatening allergies in the next several weeks. The company said Monday that the authorized generic EpiPen AutoInjector would be available at a list price of $300 per two-pack carton, or 50% cheaper than its wholesale acquisition price.

Jabbing A Needle in the Overinflated Nymox Prostate Drug Hype — It's time for some truth telling about Nymox ( NYMX) after a week in which the drug maker's stock took a long hike up Cow Feces Mountain. Nymox will not be successful convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.

Vanda Pharmaceuticals (VNDA) Stock Soars on Drug Patent Ruling — NEW YORK ( TheStreet) -- Shares of Vanda Pharmaceuticals ( VNDA) were jumping 17.53% to $13.81 on heavy trading volume mid-Thursday afternoon after a Delaware court ruled that generic drug maker Roxane Laboratories's ANDA drug violated several Vanda patents for its schizophrenia drug Fanapt, according to the Fly.
More Articles →
Sep 25, 2016

@ESchattner Thanks, Elaine. I love writing stories like this one.

Sep 25, 2016

RT @MattGoldstein26: "Our job is not stenography, but truthtelling." A true sentiment for whatever you cover. 

Sep 23, 2016

FDA approves $AMGN Humira biosimilar. Brand name: Amjevita. (Sounds like an Italian grape varietal.) Launch date? Ask the lawyers.

Sep 23, 2016

. @BrianSkorney Weekly biotech recap is one of my favorite sell-side reads. Today’s edition is a classic. A taste:

Sep 23, 2016

@CGrantWSJ @MaxJacobsEdison Bo is playing QB for Pats next Sunday. We’ll still beat the Bills.

Sep 23, 2016

@seeksup Not exactly. $SRPT allocated large part of yesterday’s deal to existing shareholders. Big accounts got most of allocation.

Are You a Journalist?

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Create a Portfolio